Krebs, Matthew G. and Forster, Martin and Majem, Margarita and Peguero, Julio and Iams, Wade and Clay, Tim and Roxburgh, Patricia and Doger, Bernard and Bajaj, Pawan and Barba, Andres and Perera, Suvini and Mueller, Christian and Triebel, Frédéric (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5 (11): 100725. ISSN 2666-3643